Nicolas Clementy

Sep 4, 2024 | jacc.org | Alexandre Bodin |Nicolas Clementy |Mathieu Nasarre |Bertrand Pierre

A 49-year-old male patient with an extravascular implantable cardioverter-defibrillator (EV-ICD) (Aurora system, Medtronic) experienced major discomfort, mainly psychological, with the device. •To understand that the extraction of the substernal lead of the EV-ICD should be performed using a dedicated workflow in a center experienced in mechanical tool use and with surgical backup. •To note that more clinical data will be needed on extraction of older leads beyond 5 or 10 years after implantation.

Jan 5, 2024 | amu.hal.science | Nicolas Clementy |Arnaud Bisson |Alexandre Bodin |Julien Herbert

Outcomes associated with pacemaker implantation following transcatheter aortic valve replacement: A nationwide cohort study Mots clés Aortic stenosis Heart failure Outcome Pacemaker Pacing-induced cardiomyopathy Transcatheter aortic valve replacement Fichier principal S1547527121017306.pdf (891.58 Ko) Télécharger le fichier Origine : Fichiers produits par l'(les) auteur(s)

Dec 4, 2023 | onlinelibrary.wiley.com | Bradley P. Knight |Nicolas Clementy |Anish Amin |Ulrika Birgersdotter-Green

1 INTRODUCTION Implantable cardioverter-defibrillator (ICD) therapy is associated with a mortality benefit for patients at risk for sudden cardiac death.1-4 Understanding the costs of ICD therapy involves not only the costs of initial implantation but also the ongoing costs related to standard device follow-up, generator changes for battery depletion, and the management of device-related complications over the life of the patient. Innovations in ICD technology can impact these costs.